NCT03057431 - Hydrochlorothiazide for Kidney Stone Recurrence Prevention | Biotech Hunter

Enrollment

416

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

December 3, 2021

Study Completion Date

April 30, 2022

Conditions

Nephrolithiasis

Interventions

DRUG

Placebo oral capsule

Once daily for 3 years

DRUG

12.5 mg hydrochlorothiazide

Once daily for 3 years

DRUG

25.0 mg hydrochlorothiazide

Once daily for 3 years

DRUG

50.0 mg hydrochlorothiazide

Once daily for 3 years

Trial Locations (12)

1011

Centre hospitalier universitaire vaudois (CHUV), Lausanne

1205

Hôpitaux universitaires de Genève (HUG), Geneva

1951

Hôpital de Sion, Sion

3010

Bern University Hospital (Inselspital), Bern

4031

University Hospital Basel, Basel

5001

Kantonsspital Aarau, Aarau

6000

Luzerner Kantonsspital, Lucerne

6500

Ospedale Regionale di Bellinzona e Valli (San Giovanni), Bellinzona

6900

Ospedale Regionale di Lugano (Civico), Lugano

7000

Kantonsspital Graubünden, Chur

8091

University Hospital Zürich, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors

lead

Insel Gruppe AG, University Hospital Bern

OTHER